https://orcid.org/0000-0003-3187-2314
About the Authors
- Josh Cone
-
Roles Formal analysis, Investigation, Methodology, Visualization, Writing – review & editing
Affiliation Alexion, AstraZeneca Rare Disease, New Haven, CT, United States of America
- Lida Kimmel
-
Roles Formal analysis, Investigation, Methodology, Writing – review & editing
Affiliation Alexion Pharmaceuticals, Inc., New Haven, CT, United States of America
- Yuchun Zhang
-
Roles Formal analysis, Investigation, Methodology, Visualization, Writing – review & editing
Affiliation Alexion, AstraZeneca Rare Disease, New Haven, CT, United States of America
- Krista Johnson
-
Roles Formal analysis, Supervision, Writing – review & editing
Affiliation Alexion, AstraZeneca Rare Disease, New Haven, CT, United States of America
- Douglas Sheridan
-
Roles Conceptualization, Formal analysis, Writing – review & editing
Affiliation Alexion Pharmaceuticals, Inc., New Haven, CT, United States of America
- Paul Tamburini
-
Roles Conceptualization, Formal analysis, Methodology, Supervision, Visualization, Writing – original draft, Writing – review & editing
* E-mail: paul.tamburini@alexion.com
Affiliation Alexion, AstraZeneca Rare Disease, New Haven, CT, United States of America
Competing Interests
JC, YZ, KJ and PT are employees and shareholders of Alexion, AstraZeneca Rare Disease. PT, KJ and DS are co-inventors on numerous patents and patent applications owned by Alexion, AstraZeneca Rare Disease and/or Alexion Pharmaceuticals, Inc. DS was an employee and shareholder of Alexion Pharmaceuticals, Inc., at the time of study and has received consultancy fees from Alexion, AstraZeneca Rare Disease. DS is now an employee and shareholder of Rallybio. LK was an employee and shareholder of Alexion Pharmaceuticals, Inc., at the time of study. LK is an employee of Arvinas, Inc. and an Arvinas, Inc. shareholder. This does not alter our adherence to PLOS ONE policies on sharing data and materials.